Notable Labs (NASDAQ:NTBL) & COMPASS Pathways (NASDAQ:CMPS) Financial Contrast

COMPASS Pathways (NASDAQ:CMPS) and Notable Labs (NASDAQ:NTBL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a summary of current ratings and price targets for COMPASS Pathways and Notable Labs, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
COMPASS Pathways	0	0	5	0	3.00
Notable Labs	0	0	2	0	3.00

COMPASS Pathways currently has a consensus target price of $47.40, suggesting a potential upside of 659.62%. Notable Labs has a consensus target price of $7.00, suggesting a potential upside of 908.94%. Given Notable Labs’ higher possible upside, analysts plainly believe Notable Labs is more favorable than COMPASS Pathways.

Profitability

This table compares COMPASS Pathways and Notable Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
COMPASS Pathways	N/A	-57.24%	-47.33%
Notable Labs	N/A	-54.54%	-43.40%

Institutional & Insider Ownership

46.2% of COMPASS Pathways shares are held by institutional investors. Comparatively, 70.5% of Notable Labs shares are held by institutional investors. 4.3% of COMPASS Pathways shares are held by insiders. Comparatively, 1.2% of Notable Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares COMPASS Pathways and Notable Labs’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
COMPASS Pathways	N/A	N/A	-$118.46 million	($2.37)	-2.63
Notable Labs	$310,000.00	4.97	-$11.26 million	N/A	N/A

Notable Labs has higher revenue and earnings than COMPASS Pathways.

Risk & Volatility

COMPASS Pathways has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Notable Labs has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Summary

Notable Labs beats COMPASS Pathways on 6 of the 9 factors compared between the two stocks.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

About Notable Labs

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.